Results from Part 1 Safety Run-in Period of a 2-part, Phase 2, Multicenter, Open-label, Proof-of-Concept Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of VP-315 in Subjects with Basal Cell Carcinoma. J of Skin [Internet]. 2023 Nov. 13 [cited 2025 Apr. 14];7(6):s260. Available from: https://skin.dermsquared.com/skin/article/view/2333